Loading...
Projects / Programmes source: ARIS

Human stem cells-advanced cell therapy II

Periods
Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   
3.01.00  Medical sciences  Microbiology and immunology   

Code Science Field
3.02  Medical and Health Sciences  Clinical medicine 
Evaluation (metodology)
source: COBISS
Organisations (3) , Researchers (23)
0311  Blood Transfusion Centre of Slovenia
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  19331  PhD Tina Cirman  Microbiology and immunology  Researcher  2012  53 
2.  20611  MSc Marko Cukjati  Microbiology and immunology  Technical associate  2012  95 
3.  15980  PhD Dragoslav Domanovič  Microbiology and immunology  Researcher  2009 - 2011  138 
4.  20605  PhD Tadeja Dovč Drnovšek  Biochemistry and molecular biology  Technical associate  2012  72 
5.  01302  PhD Matjaž Jeras  Biotechnology  Researcher  2009 - 2010  386 
6.  30968  PhD Mojca Jež  Microbiology and immunology  Young researcher  2012  101 
7.  21525  PhD Polona Klemenc  Microbiology and immunology  Researcher  2012  40 
8.  10038  PhD Miomir Knežević  Biotechnology  Researcher  2009 - 2010  296 
9.  21228  PhD Elvira Maličev  Microbiology and immunology  Researcher  2009 - 2012  166 
10.  22646  PhD Darja Marolt Presen  Biochemistry and molecular biology  Researcher  2009 - 2011  85 
11.  12336  PhD Primož Rožman  Microbiology and immunology  Head  2009 - 2012  499 
0312  University Medical Centre Ljubljana
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  11291  PhD Vane Antolič  Medical sciences  Researcher  2009 - 2012  357 
2.  21500  PhD Matej Drobnič  Neurobiology  Researcher  2009 - 2012  269 
3.  16239  PhD Dragica Smrke  Neurobiology  Researcher  2009 - 2012  483 
4.  11949  PhD Borut Štabuc  Oncology  Researcher  2009 - 2012  710 
5.  23817  PhD Samo Zver  Microbiology and immunology  Researcher  2009 - 2012  399 
7421  EDUCELL cell therapy service Ltd. Ljubljana
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  15627  PhD Ariana Barlič  Biochemistry and molecular biology  Researcher  2009 - 2012  91 
2.  25484  PhD Mirjam Fröhlich  Biotechnology  Researcher  2010 - 2011  56 
3.  28888  Danica Gantar  Pharmacy  Technical associate  2012 
4.  10038  PhD Miomir Knežević  Biotechnology  Researcher  2009 - 2012  296 
5.  19120  PhD Hana Krečič Stres  Biotechnology  Researcher  2010 - 2011  50 
6.  16002  PhD Nevenka Kregar Velikonja  Biotechnology  Researcher  2009 - 2012  347 
7.  35151  Anja Planina    Technical associate  2012 
Significance for science
Advanced therapies including cell therapies are one of the fundamental research and development orientations of biomedicine in the last decade. The proof of outstanding relevance of this field is Nobel Prize in 2012 awarded to Sir John B. Gurdon and Shinya Yamanaka for discovery that adult differentiated cells can be returned to the pluripotent state. Central questions refer to embryonic SC, which have, because of their pluripotency the best therapeutic characteristics, but their use is still controversial due to ethical concerns. Because of this alternative approaches using embryonic-like cells are very important. Alternative cell sources are post-natal and adult tissues, for example cord blood, bone marrow or peripheral blood of adults. Findings from the first part of the project (preclinical research) and the development of effective procedures for stem cell differentiation into all three germ cell layers (endo-, ecto- and mesoderm) in vitro allows us to understand the development of adult SC. This knowledge will soon help us to replace the use of embryonic SC, which is a huge step in the development of cell therapies. Cell culture in vitro and various differentiation techniques that enable us to produce mature specialized cells for example platelets will allow us to produce blood cells in vitro. In the future we will be able to grow bone marrow transplants in the laboratory. These techniques will in future replace the traditional forms of transfusions using blood donors. Findings from the second part of the project (clinical research) are the basis for wider clinical use of different types of stem and other cells. The positive outcome of these studies has led to expansion of indications for advanced cell treatments in the area of degenerative disorders of the skeletal system, wound healing, treatment of cardiovascular diseases, liver disease and cancer. Indications for the use of cell therapy are rapidly expanding, observed annual increase in these procedures is 400%. Today these techniques have already replaced organ transplants where the number of donor organs is very low, for example heart transplantation in patients with severe myocardiopathy. They also allow efficient immunoadoptive cancer therapy and are at the same time a model for other branches of clinical medicine where our methodology will be used for practical therapy in clinics in the future.
Significance for the country
The National Research Program P3-0371 - Human stem cells- advanced cell therapies II is the first of its kind in Slovenia. It has a broad and numerous range of effects. It is important because it has a direct effect on the economy and society. Quality and superior medical services enable citizens successful treatments and a high level of quality of life. Replacement of damaged or diseased tissues greatly aids to the successful treatment and rapid rehabilitation. In this way, excellent direct and indirect effects on patients and society as a whole can be achieved. It also has significance for the industry, as the advanced cell therapies have become a new branch of medicine, which in developed countries generates many new jobs. In Slovenia, the development of these technologies still lags behind. Therefore, we believe that our research program contributed to the visibility, usability and promotion of medical biotechnology. We estimate that in the new program, several jobs were open. We can expect further development of intellectual property, new international patents and the creation of spin-off companies. It is logical to expect that, like in the rest of the world, through the development of these activities in our country small medical biotech companies are created. It also has significance for social infrastructure. In the past 10 years, being aware of new flows in the world of science, we succeeded to create a solid infrastructure, human resources and solid achievements in the field of medical biotechnology. This branch of medicine is very propulsive as a manufacturing industry, being environmentally friendly and enabling sustainable development of the economy, medicine as well as medical tourism, and of the Academia, i.e. higher education and science. It also has certain relevance for public administration, cultural development, protection of natural and cultural heritage. Namely, these activities are ecologically pure and virtuous, based on the high technology and knowledge. The program is a further opportunity for international recognition of Slovenia, it allows integration at the international level, and it has opened opportunities for participation in the EU's FW7, enabled appropriate education and professional development.
Most important scientific results Annual report 2009, 2010, 2011, final report, complete report on dLib.si
Most important socioeconomically and culturally relevant results Annual report 2009, 2010, 2011, final report, complete report on dLib.si
Views history
Favourite